Stifel analyst Jonathan Block lowered the firm’s price target on Zoetis (ZTS) to $165 from $180 and keeps a Buy rating on the shares following survey work focused on recent innovation from the major Animal Health players.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Zoetis price target raised to $205 from $200 at Piper Sandler
- Zoetis’ Strong Market Position and Growth Potential Justify Buy Rating
- Zoetis price target lowered to $200 from $225 at BTIG
- Zoetis Reports Robust Growth Amid Challenges
- Zoetis reports conditional license from USDA for Avian Influenza Vaccine
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue